Satellos Bioscience Inc. (MSCL.TO)
CAD 0.89
(-4.3%)
CAD 0.89
(-4.3%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -15.7 Million CAD | -75.92% |
| 2022 | -8.09 Million CAD | -75.61% |
| 2021 | -4.6 Million CAD | -195.92% |
| 2020 | -1.6 Million CAD | 22.71% |
| 2019 | -1.99 Million CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -7.81 Million CAD | -5.72% |
| 2024 Q2 | -6.31 Million CAD | 12.65% |
| 2023 Q3 | -3.94 Million CAD | -40.36% |
| 2023 FY | - CAD | -75.92% |
| 2023 Q2 | -2.8 Million CAD | -69.45% |
| 2023 Q1 | -1.65 Million CAD | -7587.69% |
| 2023 Q4 | -5.71 Million CAD | -44.85% |
| 2022 Q4 | 22.14 Thousand CAD | 101.28% |
| 2022 FY | - CAD | -75.61% |
| 2022 Q3 | -1.72 Million CAD | 0.0% |
| 2021 FY | - CAD | -195.92% |
| 2020 FY | - CAD | 22.71% |
| 2019 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Appili Therapeutics Inc. | -2.09 Million CAD | -649.15% |
| Eupraxia Pharmaceuticals Inc. | -37.39 Million CAD | 58.003% |
| Helix BioPharma Corp. | -9.38 Million CAD | -67.27% |
| Microbix Biosystems Inc. | 1.95 Million CAD | 902.478% |
| Medicenna Therapeutics Corp. | -18.67 Million CAD | 15.881% |
| Oncolytics Biotech Inc. | -33.71 Million CAD | 53.411% |
| Sernova Corp. | -40.19 Million CAD | 60.926% |